Navigation Links
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Date:6/11/2009

targets the inflammation in atherosclerotic plaque that is thought to trigger major adverse cardiac events. Our positive Phase 2 data demonstrate VIA-2291's potent inhibition of leukotrienes, lowering of hsCRP, and the potential for plaque stabilization as demonstrated by reduction in carotid plaque inflammation and non-calcified coronary plaque volume. We believe this compound is now ready for testing in a broad outcome Phase 3 trial that may establish a link between inflammation and reduction of these major adverse cardiac events."

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
2. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
3. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
4. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
5. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
6. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
7. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
8. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today ... company at the following conferences. , Deutsche Bank ... May 29, 2013 , Presentation time: 12:00 p.m. P.T. ... , Presentation date: Wednesday June 5, 2013 , Presentation ... A live webcast and 30-day archive of these presentations will ...
(Date:5/22/2013)... Mass. , May 22, 2013  Flagship ... firm focused on healthcare and sustainability, today announced ... as a Senior Partner. In this role, ... to portfolio companies. In addition to ... Mr. Bancel also serves as President and Chief ...
(Date:5/22/2013)... , May 22, 2013  Grifols, a global ... , presented results from a study demonstrating that a ... Inhibitor [Human]) increased levels of the alpha 1 ... to levels that are considered within the normal range ... condition in which low levels of the alpha 1 ...
Breaking Medicine Technology:Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4
... Mindray Medical International Limited (NYSE: MR ... medical devices worldwide, today announced the introduction of ... A Series portfolio. This is an anesthesia delivery ... and patient monitoring systems. The products will be ...
... (NYSE: SHP ) ("ShangPharma" or the "Company"), ... outsourcing company, today announced that Ms. Wenjuan Xiao, a ... has resigned from the board, effective October 13, 2011. ... is the mother of Michael Xin Hui, the chairman ...
Cached Medicine Technology:Mindray Announces Expansion of its A Series Anesthesia Portfolio 2
(Date:5/22/2013)... 22, 2013 Jury deliberations are now underway ... a da Vinci lawsuit, Bernstein Liebhard LLP reports. ... a man who allegedly died of da Vinci surgery complications ... in damages from Intuitive Surgical, Inc. Among other things, ... for the da Vinci Surgical System in its efforts to ...
(Date:5/22/2013)... Zensah® Compression Apparel released a statement regarding ... "Breast pain while running affects one-third of women ... According to the article, a British study surveyed over ... from breast pain while running but do not wear ... , Zensah emphasizes the importance for women to wear ...
(Date:5/22/2013)... May 22, 2013 People in the United ... leading to water shortages. In much of the world, water ... water advocate, Sharon Kleyne. She warns against taking water for ... that is available so easily in the United States. , ... of Water radio show, heard live or by podcast on ...
(Date:5/22/2013)... May 22, 2013 Diversity Focus and ... This! The performance promotes awareness that physical disabilities ... Handicap This! performance will be held Friday, June 14th ... auditorium. Tickets for Handicap This! can be purchased ... audiences measure the level to which their mind is ...
(Date:5/22/2013)... ARBORA University of Michigan study challenges previous research ... Baseball. , The study, a collaboration between researchers ... Florida, looks deeper into the controversial argument over ... strikes for pitchers of the same race. It ... said Jason Winfree, associate professor of sport management ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 2Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 4Health News:Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners 2Health News:Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners 3Health News:Water Advocate Sharon Kleyne Announces Water Conservation Appreciation 2Health News:Handicap This! Comes to Marion, Iowa 2Health News:U-M study challenges notion that umpires call more strikes for pitchers of same race 2
... identify delay in key brain circuitry , WEDNESDAY, Feb. ... understanding of fragile X syndrome, which causes autism and ... , The researchers, whose findings are published in the ... developing insights into why some people with fragile X ...
... can happen to them , WEDNESDAY, Feb. 10 (HealthDay News) -- ... have fun, they just shouldn,t overlook their risk of HIV. ... up on a new campaign -- sponsored by MAC Cosmetics, nonprofit ... causes AIDS remains a potent threat to women as well. , ...
... , TRENTON, N.J. , Feb. ... that Patricia A. Barnett , a nurse and attorney with three ... Executive Officer of the Association by the Board of Directors. Barnett will ... Dr. Barbara Wright , who has been serving as interim CEO ...
... with type 2 diabetes who take a commonly prescribed class of ... for developing bone fractures. After taking a thiazolidinedione (TZD) for ... bone fracture than patients not taking TZDs, according to study results. ... are women older than 65. "Older women are already ...
... surgeons Clifford Buckley, M.D., and Ruth Bush, M.D., performed one ... GORE TAG Thoracic Endoprosthesis device for the treatment of a ... The goal of the trial is to gain insight ... (tear) as a less invasive alternative to major surgery. ...
... the world turns its sporting gaze towards Vancouver for ... Experimental Physiology marks the occasion with a special ... athletes must overcome to win gold. "When most ... images of snow and high mountains", said co-editor Mike ...
Cached Medicine News:Health News:Cyndi Lauper, Lady Gaga Put Spotlight on Women and HIV 2Health News:Cyndi Lauper, Lady Gaga Put Spotlight on Women and HIV 3Health News:Cyndi Lauper, Lady Gaga Put Spotlight on Women and HIV 4Health News:Nurse-Attorney/Former Bristol-Myers Squibb Executive Selected To Lead New Jersey State Nurses Association 2Health News:Nurse-Attorney/Former Bristol-Myers Squibb Executive Selected To Lead New Jersey State Nurses Association 3Health News:Diabetes drug ups risk for bone fractures in older women 2Health News:Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury 2Health News:Exploring the limits: Understanding the challenges facing Winter Olympic champions 2
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
Medicine Products: